Participated · Series B · May 2021

Eleanor Health delivers in-person and virtual substance use disorder care using a harm-reduction, whole-person clinical model. Its care model includes medications for addiction treatment (Suboxone and Vivitrol), psychiatry, therapy, and peer recovery coaching. Eleanor operates under value-based payment structures designed to align incentives around reduced total cost of care and improved quality metrics. The company reports improved clinical outcomes and total-cost-of-care reductions across large populations. Eleanor currently has contracts with 17 payors, including five national payors, and provides care in seven states (LA, MA, NJ, NC, OH, TX, and WA). The company intends to use new capital to continue scaling its whole-person care model and expand access. Eleanor Health operates a tech-enabled, evidence-based care model for substance use disorders and mental health that combines medication-assisted therapy, psychiatry, individual and group therapy, peer recovery coaching, health navigation, and nurse case management. The company leverages proprietary technology and data-driven personalization to enable blended telehealth and in-person community care and to drive superior clinical outcomes. Eleanor reports 84% of members improving substance use, 70% improving depression and anxiety, and an 84% reduction in emergency department and inpatient utilization. It currently operates across six markets and says it will manage more than 60,000 members by the end of 2022 and be available to over 22 million people as an in-network insurance benefit. Future plans described in the articles include fostering new risk-based, population health partnerships, expanding into Texas, and continuing to build its care delivery and analytics platform to scale its model. Eleanor Health delivers outpatient addiction and mental health care through a population- and value-based medical home model that combines in-person clinics, community-based care, and a 100% virtual option. The company provides medications for substance use disorders, psychiatric evaluation, individual and group therapy, nurse care management, support for social determinants of health, and peer recovery coaching. Eleanor operates 18 clinics and a fully virtual model across Louisiana, Massachusetts, New Jersey, North Carolina, Ohio, and Washington and plans to manage more than 50,000 members under population-based partnerships by 2022. It reports strong outcomes across its footprint, including an 84% reduction in emergency department and inpatient stays, 84% improvement in substance use, 70% improvement in depression and anxiety, and NPS/eNPS scores of 72 and 71. The company intends to scale by deepening presence in existing markets, executing additional payer contracts to manage new populations, and further developing its proprietary analytics and technology platform. Eleanor recently closed a $20M Series B to support growth and meet rising payer and community demand. Eleanor Health provides value-based outpatient addiction and mental-health treatment combining medication-assisted treatment (MAT), psychiatric evaluation, medication management, individual and group therapy, peer recovery coaching, and support for social determinants of health. The model emphasizes whole-person care delivered in outpatient clinics, community settings, and at home through technology and field-based teams, with financial accountability tied to long-term recovery outcomes. The company launched its first outpatient clinic in Mooresville, North Carolina and plans to open 10–15 sites over the next year. Eleanor Health is led by CEO and co-founder Corbin Petro and CMO and co-founder Nzinga Harrison, and its board includes health-policy leaders such as Andy Slavitt. Blue Cross and Blue Shield of North Carolina is collaborating with Eleanor Health to expand access to its services in North Carolina. Eleanor completed a major financing in July 2019 led by Mosaic Health Solutions (a Blue Cross NC subsidiary), with participation from Town Hall Ventures and Oxeon Ventures.

Participated · Series A · Dec 2020

Well operates an AI-powered health engagement system that delivers precise, personalized daily interventions and incentives to employees. The platform pairs real-time AI algorithms with concierge Well Guides (nurses, pharmacists, social workers, nutritionists, and billing experts) and an Intervention Design Lab for rapid testing and deployment. Well plans to expand its AI capabilities, enhance concierge support, and strengthen analytics to predict emerging risk patterns. The company reports strong engagement metrics—about 300 interactions per member annually, 25% of users engaging daily, and a 90 Net Promoter Score—and has demonstrated 5%+ improvements in key HEDIS measures across diverse Fortune 500 populations. Financially, Well has raised an additional $30 million, bringing total funding to over $150 million. The company is headquartered in Chapel Hill, N.C., with offices in Newton, Mass., Minneapolis, and New York City. Well Dot operates a consumer-focused health improvement platform that combines artificial intelligence, advanced behavioral economic techniques and on-demand human guidance to deliver personalized support. The company applies proprietary algorithms to a library of clinical interventions and guided experiences to support preventative care, condition management and mental health. Well partners with corporate clients and serves thousands of members, and also works with community health organizations and direct-to-consumer offerings in collaboration with consumer brands. The company plans to continue scaling operations and expand its platform to deliver enhanced functionality and improved health to more members. Well will launch with additional jumbo employer customers in 2022 while broadening access channels through employer, community and consumer-brand partnerships. Leadership includes CEO Gary Loveman and president and COO David Werry. Well is a consumer-focused health technology company that uses artificial intelligence and behavioral economics to deliver personalized health guidance. Since its founding in 2019, it has combined a consumer-grade digital platform with multidisciplinary teams of live health guides, chat and phone support, self-guided in-app actions, and rewards to engage members. The platform addresses the full spectrum of healthcare needs, including behavioral health, wellness, pharmacy, navigation, and chronic disease management, and serves all members rather than only high-cost patients. Well reports high member engagement and increased preventive actions, which the company says have led to improved health outcomes and lower costs since onboarding initial users at the end of 2019. The company plans to use the new funding to continue investing in people and technology and to expand its user base, content, and the breadth of its offerings. Financially, Well completed a $40 million Series A structured as a combination of equity and debt and previously raised $25 million in seed funding in 2019.

Participated · Series C · Oct 2014

Telcare provides a cellular-enabled blood glucose meter, a diabetes mobile application and a HIPAA-compliant cloud platform called Telserve. The Telserve cloud proactively delivers messages and reminders, offers personalized education, and captures diagnostic data while keeping patients’ doctors updated. The company’s product suite is focused on diabetes care and remote monitoring. Telcare intends to use the new funding to broaden its impact in diabetes and to expand the platform into related chronic conditions. The company is led by CEO Andrew Flanagan. Telcare is based in Bethesda, MD. Telcare develops a wireless glucose monitoring system centered on a wireless glucose meter with two-way messaging that transmits to an FDA-cleared care management server. The company also offers a suite of iPhone and Android apps to enable family members to follow the progress of loved ones with diabetes. Telcare was founded in 2008 by David Bjork, John R. Dwyer, Jr. (Chairman), and Jonathan C. Javitt, M.D., M.P.H. (CEO and Vice Chairman), and is based in Bethesda, MD. The company intends to use new capital for marketing and sales efforts, research and development initiatives, and ongoing operations. Telcare recently raised $25.5M in Series B equity funding led by Sequoia Capital with participation from Qualcomm through its Qualcomm Life Fund.